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Abstract 
The maintenance of muscle mass is important across the lifespan. The activation of 
satellite cells, followed by their proliferation and subsequent differentiation is important 
in this maintenance. Cell cycle arrest must precede differentiation, and preservation of 
the molecular networks involved within the regenerative process are necessary. 
Electrical stimulation is a common method of altering activity within a cell, and is known 
to alter the phenotype of myogenic cells. This thesis looks at the immediate effects of 
electrical stimulation on proliferating C2C12 myoblasts, in order to determine what 
induces the long term reductions in cell number associated with electrical stimulation. 
The results indicate that stimulation alters intracellular processes within these cells, 
promoting cell cycle arrest and autophagy-mediated cellular remodelling, explaining the 
long term reduction in cell number associated with stimulation. The research conducted 
is important in our understanding of muscle regeneration and muscle health. 
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1.0 - Review of Literature: 
Skeletal muscle makes up approximately 40% of human body mass, controls 
motor function and is responsible for the majority of whole body metabolism. The ability 
of muscle to regenerate and maintain itself is important in ensuring healthy muscle 
growth and functioning across the lifespan. There are many situations that arise where 
individuals cannot properly regenerate or maintain a significant amount of muscle mass 
due to injury or disease.  Therefore, an understanding of how muscle properly develops 
and renews itself following muscle injury is important. Additionally, many efforts are 
being made to understand the myogenic process in order to develop a therapy to assist 
muscle regeneration or to create whole muscle for implantation following severe trauma 
or muscle wasting.  Our lab has focused on electrical stimulation (ES) as a method of 
altering the activity within proliferating myoblasts to determine how ES affects both 
proliferation and differentiation. My thesis will focus on the adaptation and early 
responses that are important in myogenesis and cell cycle control. 
1.1 - Myogenesis: 
Myogenesis is a complex process in which skeletal muscle progenitor cells 
mature into a fully functional muscle fibre. The formation of a functional muscle fibre 
begins with the signalling of mononucleated myoblasts to fuse into a multinucleated 
myotubes. Subsequently these myotubes transform into a fully functional muscle fibre. 
Regulatory checkpoints are necessary for the complete transition from myoblast to 
myofibre, and the abundance of these checkpoints gives this process a high degree of 
complexity. Many signals have the ability to either promote or inhibit both proliferation 
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and subsequent differentiation and fusion of myoblasts into myotubes. Many of these 
cellular signals are not completely established or understood. 
Myogenesis occurs in two broad categories. First, embryonic myogenesis is the 
development of muscle tissue in a growing fetus. Second, satellite cell mediated 
myogenesis is the regeneration of muscle in response to muscle damage. There are 
many similarities between the two processes, such as common transcription factors and 
the temporal activation of genes (219), that are key to my thesis research. 
1.1.1 - Myogenic Regulatory Factors (MRFs): 
At the molecular level, muscle development is regulated by myogenic regulatory 
factors (MRFs). The MRFs are a family of basic helix loop helix (bHLH) transcription 
factors, which include MyoD, Myf5, Myogenin and MRF-4 (199). The bHLH domain is 
required for dimerization with E-protein transcription factors. Dimerization promotes the 
binding of this dimer to an E-box promoter sequence (CANNTG) on the DNA (138). 
MRFs are thought to play an important role in muscle specific gene expression, and the 
E-box promoter is highly conserved within the promoter region of many muscle-specific 
genes (199). The MRFs are expressed in a coordinated manner, and the result is a 
temporal induction of muscle-specific gene products which orchestrate myogenesis (14) 
(Figure 1). 
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Figure 1: Myogenic Regulatory Factors (MRFs) have overlapping and unique temporal 
expression which regulates myogenesis. MyoD and Myf5  have overlapping expression 
patterns throughout the early stages of myogenesis, where myoblasts are undergoing 
proliferation. Myf5 is down regulated at early differentiation, whereas MyoD remains 
expressed throughout differentiation. Myogenin and Mrf4 have overlapping expression. 
Myogenin is up regulated early in differentiation, whereas Mrf4’s expression slowly 
increases until late differentiation. As the lineage progresses from myoblast to myotubes, 
the stemness of these cells decreases, becoming more like a phenotypic skeletal muscle. 
Adapted from: C.F Bentzinger et al. 2012. Cold Spring Harb Perspect 
Biol.2012;4:a008342 
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Research shows that MRFs have both overlapping and unique functions in 
regulating myogenesis. Early research showed that MyoD and Myf-5 have a similar 
function, as markers of muscle lineage specification and are expressed within 
proliferating myoblasts. Together they are termed primary MRFs. Early work done in 
mice embryos showed that mice deficient in both MyoD and Myf-5 die soon after birth 
due to a lack of myoblasts and mature muscle (197). Interestingly, in mice that were 
only MyoD deficient, Myf-5 expression was increased and a normal muscle phenotype 
is saved (196). In contrast, Myf-5 deficient mice exhibit an abnormal muscle phenotype, 
which was not saved by a compensatory increase in MyoD (21). Taken together, this 
alludes to the overlapping and similar function of MyoD and Myf-5, but it also shows that 
each of the primary MRFs maintain a distinct role in myogenesis, necessary for a 
normal muscle phenotype to be achieved. Myogenin and MRF-4, the secondary MRFs, 
are also thought to be expressed in an overlapping fashion, sharing functional 
redundancy in promoting muscle differentiation (181). Studies conducted in mice 
embryos lacking myogenin demonstrated that myogenin is a lethal gene essential for 
muscle differentiation (151). This was not due to a deficiency in the number of 
myoblasts within these mice, but rather due to a lack of myofibres (73), suggesting that 
myogenin plays a role in promoting myoblast fusion. Comparable to the upregulation of 
Myf-5 in MyoD deficient mice, mice that are deficient in MRF-4 upregulate myogenin 
and a normal muscle phenotype is saved, alluding to the overlapping role of myogenin 
and MRF-4 (261). Interestingly, although previously thought to play a role in late 
differentiation, MRF-4 was shown to determine skeletal muscle identity in embryonic 
multi-potent stem cells when both MyoD and Myf5 are knocked down (94). Thus, 
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although functional redundancy is evident, research also shows that the MRFs hold 
unique functions, which are important to the myogenic process. 
1.1.2 - Myocyte Enhancer Factors 2 (MEF2): 
A second group of muscle transcription factors that play a pivotal role in 
myogenesis are myocyte enhancer binding factor 2 (MEF2) proteins. Within the family 
there are 4 known proteins, MEF2A-D, with A and C playing a role primarily in skeletal 
muscle development activating genetic programs associated will cell differentiation, 
proliferation, morphogenesis and survival (5, 179). Overlapping expression of the MEF2 
genes occur within skeletal muscle and this orchestrated pattern of activation and 
deactivation which skeletal muscle development (179). The MEF2 proteins are 
members of the MADS family of transcription factors, which contain a highly conserved 
MADS-box at the N-terminus, which mediates dimerization and DNA binding, thereby 
promoting gene expression (18, 244). Additionally, these proteins contain C-terminal 
regions that act as transcriptional activation domains, which are variable among MEF2 
family members (8, 17). MEF2 proteins bind to a consensus sequence within the DNA, 
(YTA(A/T)4TAR), where “Y” is a pyrimidine and “R” is a purine, and (A/T) is an AT rich 
domain within the DNA, found in the promoters of muscle specific genes, like the E-Box 
promoter for MRFs (63, 254). MEF2 binding to DNA is evident following mitogen 
depletion induction of differentiation of myoblasts but not in proliferating myoblasts (63). 
Unlike the MRFs which can induce myogenesis alone, the MEF2 proteins cannot. 
MEF2 knockdown studies show the importance of MEF2 both embryonically and 
postnatally within skeletal muscle. It seems that functional differences exist between 
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members of the MEF2 family, and the isoform specific functions differ in embryo and 
post-embryonically. Mef2A and Mef2D knockdown in mice has little effect on skeletal 
muscle development. However, when Mef2C was knocked down the mice develop 
normally in embryo, but the postnatal muscle of these mice lack sarcomere organization 
due to reduction in myomesmin, which MEF2C controls (178). Additionally, both MEF2A 
and MEF2C transcripts are highly enriched within skeletal muscle and upregulated 
during myoblast differentiation and in response to muscle damage (126, 136). However, 
MEF2A seems to be important in regulating differentiation during muscle regeneration, 
whereby knockdown of Mef2A prevents proper differentiation, yet overexpression of  
Mef2 proteins does not induce premature skeletal muscle differentiation (47, 180). This 
further develops the idea that MEF2 cannot drive muscle differentiation alone, but can 
augment the process and ensure proper muscle development.  
1.1.3 - Interplay of MRFs and MEF2s on Myogenesis: 
The MRFs and MEFs exhibit overlapping expression in both embryogenesis and 
in adulthood (43, 153). A synergistic and cooperative action between the MEF2s and 
MRFs has been shown to exist (246). Through transcriptional cooperation, the MEF2 
proteins potentiate the function of the MRFs (148). Mef2 is a gene target of bHLHs both 
in-vitro and in-vivo, identifying MEF2 as being under the control of the MRFs and 
potentiating the MRFs action in regulating differentiation (173, 237). Furthermore, the 
Mef2 promoter is a target of MEF2 protein, creating a positive feedback loop. Myogenin 
and Mrf4 gene promoters have been shown to contain MEF2 binding sites as well (31, 
153) thereby allowing for MEF2 to positively feedback and amplify their expression 
following MEF2 expression (45). This allows for added regulation within the 
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differentiation program. The interplay between the MRFs and MEF2s in inducing 
differentiation has been reviewed briefly by Potthoff and Olson in 2007 and is shown in 
Figure 2. 
 
 
Figure 2: The MRFs and MEF2 transcription factors work together to induce muscle 
differentiation in developing skeletal muscle. Signals induce expression and activate the 
primary MRFs, MyoD and Myf5, which then act to promote the expression of myogenin. 
Myogenin acts in a positive feedback manner to promote its own expression, as well as 
promoting the expression of Mef2 which is activated by various signals within the cell. 
Mef2 can feedback to promote its own expression and myogenin expression, further 
activating the differentiation plan. Adapted from: M.J. Potthoff and E.N. Olson. 2007. 
Development.  
 
1.1.4 - Muscle Regeneration and Satellite Cell Myogenesis: 
 Post embryonically, skeletal muscle is relatively stable state and in a “post-
mitotic” state. Myofibres may grow throughout maturation, but the absolute number of 
muscle fibres remains relatively constant, although day to day muscle turnover and 
repair does occur. The pathways that regulate embryonic myogenesis can provide 
important insight into the processes that control muscle regeneration, and may be 
pivotal in treating myopathies where muscle regeneration is hindered. Muscle does 
have localized stem cells which confers a vast ability to regenerate following injury. 
These cells are termed satellite cells, and can divide and give rise to cells that will 
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ultimately be incorporated into the existing mature muscle. Satellite cells can self-renew, 
shown in-vivo, whereby a single muscle fibre was transplanted with its associated 
satellite cells, contributing to regeneration and replenishment (34). Furthermore, gene 
knockdown studies determined mechanisms involved in their asymmetric division(108). 
Anatomically, satellite cells were initially found within frog muscle, and lie 
between the sarcolemma and the basal lamina of a muscle fibre, a phenomenon that 
applies to mammalian muscle as well (139). Satellite cells are easily identifiable due to 
their position within the muscle. They are described as “wedged” between the plasma 
membrane of and the basement membrane of a muscle fibre, with the satellite cell 
pushing on the myofibrils within the muscle cell (74, 139). The location of satellite cells 
is of upmost importance, whereby they have a higher density around capillaries, 
myonuclei and motoneuron junctions, suggesting a role that these structures play in 
regulation of satellite cells (74). Morphologically, satellite cells are mononucleated with 
highly condensed chromatin, a large cytoplasm, and very few organelles, analogous to 
multi-potent stem cells.  Figure 3 outlines the anatomy and morphology of a satellite cell 
within a muscle fibre, and shows a myonuclei to draw comparison to. 
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Figure 3: Quiescent satellite cells are found beneath the sarcolemma but above the basal 
lamina of a muscle fibre. Unlike a myonuclei, these cells are not within the muscle fibre, 
and these cells have highly condensed chromatin within them in comparison to myonuclei.  
Adapted from: Hawke and Garry, 2001. Journal of Applied Physiology.  
 
In early development, satellite cells divide to provide myonuclei to growing 
muscle fibres, whereas in mature skeletal muscle these cells are found to be quiescent 
and only function when signalled to become active, as in muscle regeneration (3, 150, 
205). Many models have been utilized to induce muscle injury – such as crushing the 
muscle, freezing the muscle, or using chemicals such as cardiotoxin to cause muscle 
injury (74). Furthermore, exercise has been utilized as a method of injuring muscle, 
showing the importance of this cell population in both muscle regeneration and the 
maintenance of muscle mass as an adaptation to exercise (39, 85, 194, 195, 234).  
The process is strikingly similar to that of embryonic myogenesis in terms of 
networks that promote proliferation and subsequent differentiation and fusion of these 
cells. Both processes require MRF and MEF2 transcription factors to promote muscle 
specific gene expression. Interestingly, quiescent satellite cells from isolated muscle 
fibres do not express MRFs of MEF2s but do during proliferation and differentiation 
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(249). Quiescent satellite cells do however express the paired box transcription factor 
Pax7. This is different from embryonic precursors that express Pax3, which controls 
commitment of somatic precursors to the muscle lineage, MyoD and Myf5 expression, 
and migration of muscle precursor cells (11, 19, 20, 54, 135, 220). Pax7 deficient mice 
lack the ability to form muscle post-natally,  and mutated Pax7 in skeletal muscle leads 
to a complete absence of satellite cells, yet when Pax7(+) satellite cells were 
transplanted back into the Pax7 mutant animal, muscle regeneration was rescued (200, 
206). A different study found that Pax7(-/-) animals display a significant reduction in 
satellite cell content, yet sufficient satellite cells numbers exist to aid in regeneration, 
albeit with less efficiency (164). Together, these findings show the complexity and 
integral role Pax7 plays as a specification factor for satellite cells.  
Activation, proliferation and differentiation of satellite cells are all integral to the 
regeneration and inhibition of any of these processes hinder the regeneration (183). The 
activation of satellite cells is promoted following muscle injury and the associated 
inflammatory response, where they are now similar to myoblasts. Satellite cells have the 
ability to respond to a variety of factors such as hepatocyte growth factor and fibroblast 
growth factor which promote proliferation, transforming growth factor beta which inhibits 
proliferation and differentiation, insulin-like growth factor which promote proliferation and 
differentiation, interlueken-6 and leukemia inhibition factor which promote regeneration 
(30, 36, 110–112, 125, 185, 208, 210, 211), reviewed in (74). 
These activated satellite cells will proceed to proliferate, differentiate and fuse 
into the damage muscle fibre. At quiescence Pax7 is expressed, whereas MyoD and 
Myf5 are not (37, 206). Following activation there is an increase in the transcripts of 
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primary MRFs, MyoD and Myf5, with continued expression of Pax7(37, 206, 217, 249). 
At the onset of differentiation there is an increase in the secondary MRFs, specifically 
myogenin, thereby promoting differentiation (37, 217, 249). Cell culture models have 
shown that Pax7 decreases the transcriptional activity and stability of MyoD, thereby 
repressing myogenin expression, and when myogenin is ultimately elevated, Pax7 
transcription is repressed  (160, 161). The ratio of Pax7 and MyoD is implicated in 
determining satellite cell fate. High Pax7:MyoD promotes quiescence, intermediate 
Pax7:MyoD allows for proliferation, and when Pax7:MyoD is low and myogenin is 
elevated these cells differentiate (253). Differentiation is associated with increases in 
myogenin, MRF-4 and  Mef2 expression, all of which are promoted by the increasing 
MyoD (15, 173, 217, 249). The ratio of increased MyoD:Pax7 associated with 
proliferation and differentiation may be due to decreases in Pax7, thereby alleviating the 
transcriptional repression it has on MyoD. A summary of the complete process and the 
temporal expression of the genes involved are shown in Figure 4. 
 
 
 
 
Figure 4: Gene expression of Pax7, MRFs and MEF2 differ throughout satellite cell mediated muscle 
regeneration. Quiescent satellite cells express only Pax7. Once activated, satellite cells proliferate the 
these myoblasts express both Pax7 and primary MRFs, MyoD and Myf5. After induction of differentiation, 
Pax7 is down regulated, whereas Myogenin and MEF2 are expressed to promote differentiation  
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1.2 - Cell Cycle: 
 
During the cell cycle, a cell undergoes DNA replication followed by the division 
into 2 identical daughter cells (202). The cycle can be broken down into four stages. 
The initial growth and preparation phase is termed gap-phase 1 (G1), and in this phase 
the cell readies itself for DNA replication. Following this phase, the DNA synthesis 
phase (S) occurs, in which the DNA physically replicates, doubling chromosomal 
number. The second gap-phase (G2) follows and during this phase newly synthesized 
DNA is checked for abnormalities and the cell prepares for division. The final major 
stage in the cell cycle is the physical splitting of the cells which occurs in the mitotic (M) 
phase. Additionally, there is a G0 phase, in which a cell is no longer cycling, but has the 
ability to enter the cycle at G1 if prompted to (233). 
1.2.1 - Function of CDKs, Cyclins and CKIs: 
The cell cycle is a very tightly regulated process, and checkpoints permit or 
prevent the progression  through the process. An overview of the process is shown in 
Figure 5. The eukaryotic cell cycle is regulated by the interaction of cyclin-dependant 
kinases (CDKs) and cyclins (134). Pairing of a CDK with its associated cyclin promotes 
cell cycle progression, via phosphorylation of select targets which subsequently effect 
downstream processes (229). Cyclins get their name because they are expressed 
cyclically throughout the cell cycle. Temporal waves of expression match different 
transition points such as G1-to-S, G2-to-M, and M-to-G0 (16). Added complexity comes 
from protein inhibitors of the cell cycle, termed CDK-inhibitors (CKIs). Two families of 
CKIs functionally inhibit the cell cycle. One is the inhibitor of CDK4 activity (INK4)-family 
of proteins (p15-p16, p18, p19) and the other is the kinase-inhibitory protein (KIP) - 
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family proteins (p21, p27, p57). INK-proteins form a complex with CDK 4 and 6, 
preventing their association with cyclin D(25). KIP-family proteins inactivate CDK-cyclin 
complexes and have higher affinity when cyclins are associated with CDKs rather than 
CDKs alone (67, 164, 218). 
Figure 5: Stages of the mammalian cell cycle. The G0 phase is a quiescent stage, and when prompted to 
a cell will enter the cell cycle, beginning with G1, where the cell readies itself for DNA replication. In S-
phase DNA will replicate, followed by G2, where the cell readies itself for cell division in the M-phase. 
Interactions of cyclins and their associated CDKs (green) promote cell cycle entry, while members of the 
KIP and INK family (red) act as cell cycle inhibitors, preventing progression through the cell cycle. 
Adapted from: Donovan and Slingerland, 2000. Breast Cancer Res.  
1.2.2 - Regulation of the Cell Cycle: 
Regulation differs at various points throughout the cell cycle, but the key to cell 
cycle progression is that the drive from cyclin/CDKs must be greater than the inhibition 
of the CKIs. During the G0 phase, all cyclin/CDK complexes are inhibited with cyclin 
levels being low and CKI levels being high, which prevents cell cycle entry. Additionally, 
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hypophosphorylated retinoblastoma protein (pRb) is inhibiting E2F transcription factors, 
thereby impeding the expression of genes necessary for S-phase entry (95, 130). 
Cell cycle entry at the G0/G1 transition is regulated by cyclin D and CDK4/6. 
Prior to, and early in G1 there is an increase in cyclin D isoforms, which associate with 
and activate CDK4 and CDK6 (134, 182, 221). In addition, localization of cyclin D within 
the nucleus is important to promote cycling and S-phase entry (12). A target of the 
cyclin/CDK complex formed in at the G0 is pRb. Hyperphosphorylated pRb is unable to 
bind and inhibit E2Fs, thereby alleviating the transcriptional repression put on E2F by 
pRb promoting S-phase entry (9, 95). Once this point is reached, the cell will be 
committed to DNA duplication (202). This is the only phase within the cell cycle where 
both INK and KIP families of CKIs have the ability to inhibit the cell cycle(212, 213). 
Cyclin E and CDK2 are important in regulating late G1, the G1/S transition, and 
entry into the S phase. Cyclin E expression is cyclical, reaching maximal expression in 
late G1 and dropping during S-phase as cyclin A levels begin to rise (104). 
Overexpression of cyclin E shortens G1 and promotes entry into S-phase, and silencing 
of cyclin E leads to abnormal G1/S transitions (157). Knockdown of cyclin E is 
embryonic lethal in mice, while knockdown of CDK2 is not, indicating the importance of 
cyclin E in cell cycle progression (60). 
To progress through the G1/S checkpoint a cell must overcome the inhibition of 
KIP proteins in G0 and G1 (33). In addition to cyclinE/CDK2, the association of cyclin A 
with CDK2 is important at the G1/S transition and progression through S-phase. 
Inhibition of cyclin A prevents its nuclear accumulation and DNA synthesis (62). KIP 
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family of proteins can impede the formation of cyclinE/CDK2 and cyclinA/CDK2 
complexes at this point within the cell cycle (213). p27 is elevated in quiescent cells and 
reduced in cycling cells, and has the ability to induce G1/S arrest through nuclear 
interactions with cyclinE/CDK2 or cyclinA/CDK2 (7, 156). At this stage p21 can also 
inhibit the cell cycle (236). Interestingly, p21 has an E-box in its promoter linking MyoD 
to inhibition of the cell cycle (67). In order to proceed through to S-phase, a cell must 
overcome this inhibition (212).  
Following DNA replication, the S/G2 checkpoint is reached. Throughout G2, the 
cell will prepare itself for cell division, and check DNA integrity. G2 and the G2/M 
checkpoint are tightly regulated by the CyclinB/A/CDK1 complex. Substrates for these 
complexes are nuclear laminins and microtubules that aid in cytoskeleton formation to 
assist in the division process (98). KIP cell cycle inhibitors have the ability to inhibit the 
cell cycle at this point. If DNA damage is detected, tumor suppressor p53 is expressed 
and transcriptionally promotes p21 expression thereby arresting the cell cycle (140). 
Cancer cells treated with anti-cancer agents show elevations in p21 and p27 and cell 
cycle arrest at G2/M (247). Further, in response to DNA damage, p27 deficient mice 
lack cell cycle arrest at the G2/M, and accumulate damaged DNA, indicating a role of 
both p21 and p27 in arresting the cell cycle in response to various cues in G2 (172). 
Following the G2/M checkpoint, a cell will divide and the daughter cells will proceed 
through the process again as long as the appropriate signals are present. 
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1.2.3 - Myogenesis and the Cell Cycle: 
The shift from proliferation to a cyclically arrested and terminally differentiated 
state is integral to myogenesis. First, quiescent satellite cells must be activated and 
enter the cell cycle. These proliferating cells are in a state of continuous cell cycling and 
cell cycle arrest must precede differentiation for proper progression of myogenesis. An 
understanding of the cell cycle and its regulation throughout myogenesis has important 
implications in muscle regeneration. A summary of how the cell cycle and myogenesis 
function together is shown in Figure 6.  
 
 
 
Figure 6: The interplay of the cell cycle and myogenesis. Following activation of quiescent progenitors, 
myoblasts will upregulate MyoD and Mf5 and proliferate. At this time the cell cycle proteins are overriding 
the inhibition put on them by cell cycle inhibitors (p21,p57 and p27). Following a signal, cell cycle arrest 
will precede differentiation. These terminally differentiated mononucleated myocytes will begin to express 
Myogenin and MRF4 which will promotes fusion and the formation of multinucleated myotubes 
 
As with all cell cycle entry, CKI inhibition is overcome by cyclin/CDK drive which 
promotes the proliferation of satellite cells. It has been proposed that quiescence is 
regulated by Myf5 because its expression is high in G0 and G2, whereas cell cycle entry 
and early proliferation of satellite cells is regulated by Pax7 and MyoD, whereby MyoD 
is highly expressed in G1 (102, 227). Furthermore, MyoD is a transcriptional activator of  
p21, allowing it to control proliferation post-activation (67, 70, 102, 160, 227). However, 
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in activated and proliferating satellite cells  MyoD is inhibited by Pax7 (256). 
Furthermore, CyclinE/CDK2 and CyclinD/CDK4 complexes, which are elevated as the 
cell is cycling, promote the degradation of MyoD,  thus reducing p21 expression and 
MyoD induced cell cycle arrest and therefore the onset of differentiation (66, 227, 259). 
Interestingly, AKT activation during proliferation stabilizes p21 by phosphorylation on 
T155 and S146, allowing p21 to assist in the assembly and activation of 
cyclinD/CDK4/6, promoting cell cycling (121). Furthermore, cyclin D null mice lack the 
proliferative capacity of their wild type counterparts, making it important in satellite cell 
cycle entry (129). Cyclin D prevents MyoD from transcribing p21 expression, thereby 
preventing MyoD induced onset of differentiation (204, 206). In addition, CDK4 can 
block myogenin and MEF2 activation, further preventing premature differentiation (117). 
When sufficient conditions are met the differentiation program will be initiated. 
However, this is dependent on cell cycle exit. CKI activity must be greater than that of 
the cyclins/CDKs and the negative regulation of MyoD and p21 that promoted 
proliferation and prevented premature differentiation must be alleviated (103). 
Importantly, MyoD-/- myoblasts display delayed differentiation(187), whereas Myf5-/- 
myoblasts exhibit early differentiation, indicating that MyoD is important in promoting 
cell cycle withdrawal and the onset of differentiation, likely through p21 (149, 198). 
Following the induction of differentiation, cyclins A, B, D1, and E are down regulated, 
promoting cell cycle withdrawal (86). The reductions in cyclin D1/2 are GSK-3β 
mediated and these reductions are integral in promoting differentiation because forced 
elevations of cyclin D1/2 induces continued proliferation of myoblasts (40, 168). In 
contrast cyclin D3 is unchanged at the onset of differentiation, however it promotes 
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skeletal muscle specific cell cycle arrest through MyoD and p21 (28, 70, 75). Although 
p21 is a transcriptional target of MyoD, it is expressed in myoblasts even when MyoD is 
knocked down, suggesting that other factors contribute to p21 expression (169). 
Following the onset of differentiation, p57 is also upregulated and promotes cell cycle 
arrest through inhibition of cyclinE/CDK2, likely by preventing the associated breakdown 
of MyoD by cyclinE/CDK2 (189). Interestingly, p21/p57 double knockout mice show over 
proliferation of muscle precursors and lack terminal differentiation leading to deficits in 
muscle mass (260). In addition to p21 and p57, p27 is upregulated in differentiation and 
is implicated in skeletal muscle cell cycle arrest (32). Its expression is transient in the 
myotomes of mice embryos, important in short term cell cycle exit by enhancing MyoD-
initiated myogenesis, whereas in fully differentiated myocytes expression of p27 is 
elevated (141, 255), likely holding the cell in an arrested state. Recently, loss of p27 
was shown to promote proliferation, and impair satellite cell renewal following injury and 
impairs differentiation, potentially through its effects on MyoD (29, 141). The CDKs and 
CKIs are precisely regulated and work co-operatively with myogenic factors to ensure 
that cell cycle arrest precedes differentiation.  It is now, following withdrawal from the 
cell cycle, that the expression of myogenin and other differentiation related factors are 
elevated and differentiation occurs (6). 
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1.3 - Myogenic Regulation: 
 There are regulatory inputs that muscle progenitors receive which have the ability 
to promote or prevent proliferation, cell cycle arrest, and differentiation. The myogenic 
program has the ability to be altered by extracellular signalling which transduces its 
signal internally. This section will review some of the signalling networks that exist within 
skeletal muscle myoblasts and the potential effects of altering such networks. 
1.3.1 - Regulation by AKT: 
One source of regulation is through AKT. In a sub confluent and growth factor 
rich state, AKT is thought to promote cell cycle progression, whereas at confluence and 
growth factor poor environments, it is thought to promote cell cycle exit and 
differentiation (103). Thus keys to regulating AKT may be cell-to-cell contact and growth 
factor availability (103). An overview of AKTs differential effects is seen in Figure 7. 
AKT promotes proliferation in a variety ways. One way it does so is through the 
regulation of p27 localization and stability. p27 is phosphorylated by AKT on the T157 
residue, stabilized it within the cytoplasm, preventing its nuclear import and association 
with CDKs and cyclins (123). Furthermore, AKT promotes proliferation by preventing 
p27 gene expression through inhibition of FOXO transcription factors (22, 30, 105, 133). 
FOXO can also reduce cyclin D  levels directly or through GSK-3β mediated 
phosphorylation of cyclin D on T286, which promotes its nuclear export and degradation 
(40, 214). Thus, inhibition of FOXO and GSK-3 by AKT will promote cycling (204). In 
addition, AKT stabilizes p21 by phosphorylation on T155 and S146, which assists in the 
assembly and activation of cyclinD/CDK4/6, promoting cell cycling (121). Furthermore, 
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AKT1, but not AKT2 is required for proliferation, by phosphorylating p21 on T145, 
preventing AKT2 mediated cell cycle arrest (79). In conclusion, AKT activation can act 
on FOXO, p27, p21, and promote proliferation. 
AKT activation promotes cell cycle exit and subsequent differentiation when 
myoblasts reach confluence and proper growth conditions are met (103). AKT2 
prevents the proliferative effects of AKT1 on p21 and promote cell cycle exit (79, 80). 
Furthermore, AKT acts on pathways which destabilize cyclin D and promote cell cycle 
exit and can promote differentiation potentially though MyoD (61, 80). Myogenin activity 
is pivotal for the terminal differentiation of myoblasts and is necessary for skeletal 
muscle fibre formation and is under the control of AKT through GSK-3β (188). 
Constitutively active GSK-3β represses myogenin transcriptional activity without 
affecting its protein level. Overexpression of GSK-3β represses myogenin, thereby 
preventing differentiation in C2C12 myoblasts(41). Active AKT inactivates GSK-3β 
through phosphorylation on the Serine 9 residue, alleviating the repression it has on 
myogenin expression which promotes differentiation (232). IGF-1 signaling pathways 
that activate AKT lead to inhibition of GSK-3β activity and promotes differentiation (38, 
167, 191). Furthermore, in response to AKT activation, GSK-3β may target MEF2 post-
translationally, as the inhibition of GSK-3β enhances MEF2A/D expression and 
transcriptional activity (42). 
 
 
21 
 
 
  
 
 
 
 
Figure 7: Differential regulation of myogenesis by AKT in a proliferative sub-confluent 
state (left) and a confluent state (right). In a sub-confluent state, AKT promotes cell 
cycling and proliferation, whereas in a confluent state it promotes cell cycle exit and 
differentiation. 
 
1.3.2 - Regulation by Mitogen-Activated Protein Kinases (MAPKs):  
Mitogen-activated protein kinases (MAPKs) such as extracellular signal-regulated 
kinase 1 and 2 (ERK1/2 or p42/p44-MAPK) and p38-MAPK also regulate the myogenic 
process. Both MAPK families are activated by mitogen stimulation, but their activation 
networks and functions differ, whereby the ERKs act on proliferation and differentiation, 
and p38-MAPK are implicated in differentiation only. 
ERK1/2 (p42 and p44) are MAPKs that are activated in response to growth 
factors and mitogens. A receptor tyrosine kinase transduces an extracellular signal and 
through sequential phosphorylations of Raf1 and the MAPK-kinases MEK1 and MEK2, 
which leads to phosphorylation of the ERKs (84, 163, 190). Phosphorylation of ERK1/2 
allows for its nuclear translocation where it activates transcription factors via 
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phosphorylation(101). The ERKs are thought to play a dual role myoblast proliferation 
and differentiation because of their ability to respond to stimuli for both proliferation and 
differentiation, and phosphorylate many targets. Early in the myogenic program ERK 
activity is implicated in being stimulatory to proliferation and inhibitory to differentiation, 
although the reverse is true late in the myogenic program, suggesting different ERK 
mediated mechanisms are involved in proliferation and differentiation (1, 144, 245). 
The ERKs have been implicated in the promotion of proliferation in fibroblasts 
and adipocytes through cell cycle regulation (166, 177), and this is true within myoblasts 
as well. In myoblasts the forced inactivation of ERK1/2 prevents proliferation and blocks 
cells at G1/S and the activation of ERK1/2 promotes proliferation (78, 88). This is 
through increasing cyclinD1 expression (116). In addition, ERK1/2 decreases p27 
protein levels through an ERK-dependant phosphorylation-mediated degradation of p27 
and in MCF7 breast cancer cells ERK1/2 activation promotes p27 nuclear export and 
degradation, although other research indicates otherwise (53, 107, 187). This shows the 
complexity of the system and that further evaluation is required to determine the specific 
role the ERKs play temporally in myogenesis. ERK1/2 may also prevent the onset of 
differentiation by inhibiting MEF2 nuclear translocation and preventing MyoD and 
myogenin from activating differentiation specific genes via Fos and Jun activation (120, 
242). Together this indicates the importance of ERK in maintaining a proliferative state 
within myoblasts although the mechanisms are not fully understood and require further 
evaluation. 
ERK is also important in promoting differentiation as well, although the role it 
plays in the transition between proliferation and differentiation is not well understood. 
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However, recent evidence suggests that the shuttling of ERK between the nucleus and 
cytoplasm is what drives proliferation (nuclear) or differentiation (cytoplasmic) (142). 
Following cell-to-cell contact and mitogen depletion, ERK activation decreases, which 
may be mediated by AKT activation (64, 192, 235, 250). However, evidence suggest 
that ERK activation substantially increases to assist in differentiation of myoblasts (64, 
163). Moreover, FGF inhibition prevents ERK1/2 activation and promotes cell cycle exit 
and differentiation (142). Likewise, inhibition of MEK and thus ERK1/2 promotes 
differentiation associated with an increase in MyoD and myogenin (4). The inactivation 
of ERK1/2 at the onset of differentiation promotes the expression of MyoD (64), through 
reduced AP-1 activation, which then leads to increased p21 expression (163) and cell 
cycle arrest. Thus a decrease in ERK activity may promote the onset of differentiation. 
Further, ERK2, and not ERK1, is required for terminal differentiation of myoblasts(119), 
developing the idea that differential regulation of the ERKs may be important in 
myogenesis. All together the research indicates the important role ERK activity plays in 
early proliferation, differentiation and the transition between the processes. The 
intricacies of the system are not well defined and warrant further investigation. 
Another MAPK is p38-MAPK, which is activated by an upstream MAPK Kinase 
(MKK or MAPKK), specifically MKK3 and MKK6(46, 84, 190). Four isoforms of this 
protein exist; α,β, γ, and δ, with the α isoform being most important within muscle (257). 
The kinase activity of p38 increases throughout differentiation (162) where it is thought 
to promote cell cycle exit and activate proteins associated with differentiation. 
Knockdown of p38α in cultured and neonatal muscle induces continued proliferation and 
delayed maturation of musculature (174). Cell cycle exit may be promoted by p38 
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through inhibition of cyclinD1 transcription and protein expression, and knockdown of 
p38α leads to elevated cyclinD transcription through activation of JNK/cJun mediated 
transcription (116, 174). Most importantly, MEF2 proteins contain MAPK 
phosphorylation sites that are only responsive to p38-MAPK and not ERK1/2 (162). p38 
activation increases the expression of MEF2 responsive genes, and MEF2A seems to 
be the preferred substrate for active p38, but all MEF2 proteins are able to be activated 
by p38 (162, 262). In concert with this, MEF2C phosphorylation by p38 of enhances its 
transcriptional activity (71). Inhibition of p38 in myoblasts prevents the differentiation 
program, while activation of p38 stimulates muscle differentiation, through its ability to 
indirectly activate MyoD and directly phosphorylate and activate MEF2 (T312 and 319) 
thereby stimulating muscle differentiation (245, 251, 262). Specifically, active p38 
phosphorylates E47 allowing it to dimerize with MyoD and enhances MyoD activity, and 
may be further mediated by p38’s activation of MEF2C, a coactivator of MyoD (127, 
258). p38 activity promotes the binding of MyoD and MEF2 to late-activated promoters, 
and forced expression of p38 early in differentiation promotes the expression of late 
differentiation genes (173) . Most recently, p38 activity has been shown to be important 
in both early and late differentiation, where inhibition prevents both the onset of 
differentiation and the fusion of cells in late differentiation (59). Together this suggests 
an important role of p38-MAPK in regulating myogenesis, more through its 
differentiation effects than its cell cycle effects. 
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1.3.3 - Regulation of the Cell Cycle by AMPK and p27: 
 AMPK, an energy sensitive kinase within the cell is activated when the AMP:ATP 
ratio is increased, which is indicative of compromised energy status. It is 
phosphorylated on the T172 residue, when its own phosphorylation site is exposed, by 
the highly ubiquitous kinase LKB1 (209, 248). A second, LKB1 independent 
mechanism, that activates AMPK is in response to increases in intracellular calcium 
(Ca2+), whereby [Ca2+]IC increases the activity of Ca
2+-Calmodulin-Dependent Protein 
Kinases (CAMKs) and in muscle cells specifically, CAMKII (76, 184, 193). Inhibition of 
CAMKII prevents AMPK activation in response to Ca2+ treatment (81, 243). This is 
especially important in muscle because following excitation of a muscle fibre from a 
motor neuron, there are transient increases in [Ca2+]IC (27). 
Classically, AMPK has been studied in functional muscle, in the context of 
metabolism (184). Its activation in response to stressors such as low nutrient availability 
or prolonged exercise are well established (143). In addition, AMPK has profound 
effects on the cell cycle, whereby its activation promotes cell cycle arrest (82, 152). 
AMPK was very recently shown to cause cell cycle arrest in G-361 human melanoma 
cells deficient in LKB1 via the activation of CAMKII by Ca2+ (50). Thus, in muscle, AMPK 
activation by both LKB1 and CAMKII have important cell cycle ramifications. 
AMPK mediated cell cycle arrest has been found to occur at G0/G1 in various 
cancer cell types by increasing p21, p53, and p27 protein levels via post-translational 
modifications (24, 175, 186). Interestingly, increases in non-CDK bound p27 are found 
following growth stimulation, but decreases in non-CDK bound p27 are found in 
situations of metabolic stress, pointing to increased affinity of p27 for cyclin/CDK 
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complexes following post-translational modifications (17).One possible mechanism 
behind AMPK mediated cell cycle arrest is the phosphorylation of  p27 on T198 
stabilizes p27 and promotes cell cycle arrest through cyclin/CDK inhibition and 
autophagy and not apoptosis (114, 115, 122). Additionally, AMPK mediated cell cycle 
arrest has been shown to include p53 phosphorylation (S15 and S18) and activation, 
which increases p21 transcription, thereby augmenting and inducing cell cycle arrest 
(89). 
The effect of AMPK on muscle development and myogenesis has not been 
deeply investigated, but AMPK has been shown to regulate the process. AMPK 
promotes myogenin expression, however, inhibition of AMPK reduces myogenin 
expression and prevents myogenesis from occurring through HDAC5 activation (55, 
56). Moreover, there is a temporal expression pattern of AMPK that changes as a 
myoblast differentiates which may be important for satellite cell mediated regeneration 
(155). AMPK activation by AICAR inhibits myogenic differentiation when cells are in a 
differentiation medium (145). In a proliferative state in which cells were starved of 
glucose, AMPK activation was proposed to block differentiation by increasing 
intracellular NAD+:NADH, which is sensed by SIRT1 (57). Furthermore, adiponectin 
treatment of proliferating C2C12 myoblasts promotes AMPK activation, differentiation 
and the expression muscle specific markers but not as effectively as differentiation 
media and similar to the effects of AICAR, however the effect was reduced by the 
AMPK inhibitor compound C (49). Thus the method of activating AMPK seems 
irrelevant, and its activation appears promote cell cycle withdrawal differentiation. 
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1.4 - Autophagy: 
 Autophagy is an intracellular degradation system, in which cellular components, 
such as organelles and proteins, are used for liberation of ATP. Contents are targeted, 
isolated in a double membrane (autophagosome) and delivered to the lysosome to be 
broken down and recycled for energy liberation. The process is catabolic in nature and 
highly regulated. Basal autophagy is conducted within cells and is important in 
degradation of damaged proteins and organelles to ensure proper cell function and 
homeostasis (96). Interestingly, there is interplay between the ubiquitin proteasome 
system (UPS) and autophagy, in which inhibition of one system promotes the other 
system to ensure targeted protein breakdown within the cell, which was found to the 
case in cardiac muscle (263). The UPS is thought to degrade short lived proteins, 
whereas autophagy is thought to degrade long-lived proteins, but many proteins can be 
degraded by both systems (154). 
1.4.1 - Overview of Autophagy: 
 There are 3 types of autophagy: macroautophagy, microautophagy and 
chaperone-mediated autophagy (109). Macroautophagy is of interest in my thesis. 
Autophagy begins with the selection of cargo, followed by initiation of autophagy where 
a phagophore undergoes nucleation and expansion into an autophagosome, and 
completion of the double membrane autophagosome (13). The cellular constituents are 
engulphed in the autophagosome, which fuses with a lysosome, now termed an 
autolysosome (13, 109). The contents are subsequently broken down by the acidic 
contents and hydrolases of the lysosome, and energy is liberated and the by-products 
are exported by permeases to be reused within the cell (13, 77, 96, 109). 
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The process is tightly regulated by autophagy related genes (ATGs) and other 
proteins. The initiation of autophagosome formation is regulated by the ULK1/2-ATG13-
RB1CC1 or ULK1/2-ATG13-FIP200 complex (13, 170). This complex and thus the 
initiation of autophagosome formation is regulated by mammalian target of rapamycin 
(mTOR). When mTOR is bound to this complex, it inhibits the initiation of autophagy by 
phosphorylating and preventing dephosphorylation of ULK1/2, which  prevents FIP200 
and Atg13 phosphorylation (90, 170) When mTOR dissociates from this complex, 
ULK1/2, are dephosphorylated and can phosphorylate FIP200 and ATG13, thereby 
activating autophagy (90, 93, 170). Knockdown of ATG13 and inhibition of mTOR 
prevent autophagosome formation making these important targets in the regulation of 
autophagy (90). 
Nucleation of the phagophore involves the recruitment the ATG14 complex, 
which contains class III phosphatidylinositol 3-kinases (PI-3-Ks). The complex is made 
up of ATG14-BECN1-PIK3C3-PIK3R4 (170), and is negatively regulated by BCL2 
binding to Beclin-1 thereby preventing Beclin-1 association with the complex (171). 
Knockdown or dissociation of BCL2 from Beclin-1 promotes autophagy (13, 124, 171).  
Subsequently, the phagophore elongates and expands to become an 
autophagosome. Two conjugation systems regulate this process, the ATG12-ATG5-
ATG16L1 conjugation complex and the LC3 conjugation system (170). The ATG12-
ATG5-ATG16L1 is irreversibly formed by E1 and E2 activating enzymes that link 
ATG12-ATG5. The ATG16L1 then binds to ATG5, which promotes dimerization with an 
identical complex(146). This complex interacts with the phagophore membrane and the 
second conjugation complex, dissociating when the full autophagosome is formed 
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(147). The LC3 conjugation system relies on ATG4, a protease that processes LC3 into 
LC3-I in order for it to conjugate with the membrane of the phagophore (241). LC3-I is 
then activated by an E1-like enzyme (ATG7) which allows it to be processed by an E2-
like enzyme (ATG3) and subsequently interacts with the ATG12-ATG5-ATG16L1 
complex which acts like an E3-ligase, conjugating a phosphatidylethanolamine (PE) to 
the LC3, now termed LC3-II (170). LC3-II is the lipidated form of LC3 and is correlated 
with the extent of autophagosome formation, as it associates proportionally with the 
membrane of autophagosome (91, 224). ATG9 is also thought to assist in elongation by 
recruiting more membrane for the autophagosome. 
The autophagosome is now proceeding towards completion and must fuse with a 
lysosome, forming an autolysosome, which involves cell trafficking, tethering, and fusion 
of the two membranes to allow for digestion of the contents. This is regulated by 
microtubules, SNARE proteins and SNAP proteins (13, 170). Figure 8 represents a 
summary of the autophagy pathway discussed above. 
1.4.2 - Regulation and Markers of Autophagy: 
Important to my work is how autophagy is involved in the response to cellular 
stressors, such as nutrient deprivation, starvation, damage to organelles and alterations 
to the intracellular components of a cell. AMPK has been shown to be an activator of 
autophagy, as is within electrically stimulated myoblasts (44). AMPK is also activated in 
situations of low energy and when active for prolonged periods it promotes autophagy 
(68, 83). It does so through either a TSC1/2 mediated inactivation of mTOR or 
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interaction with ULK1/2 (99, 100, 225). Therefore, AMPK is an important energy sensing 
target within a cell that can regulate autophagy in situations where nutrients are low. 
Interestingly AKT, ERK1/2, and p38-MAPK can all inhibit autophagy and all are 
important in skeletal muscle differentiation. AKT can prevent autophagy, by activating 
 
 
 
 
 
 
 
 
 
Figure 8:  Autophagy is a multi-step process that begins with initiation and nucleation which 
are regulated by ULK1/2-ATG13-FIP200 and ATG14-BECN1-PIK3C3-PIK3R4 complexes. 
Elongation and closure of the phagophore follows and is mediated by the ATG12-ATG5-
ATG16L1 and LC3 conjugation systems. Fusion of the autophagosome with the lysosome 
produces an autolysosome which degrades the contents and the by-products are released into 
the cytosol be lysosomal permease. 
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mTOR through inactivation of TSC1/2 and AMPK (69) or by phosphorylating Beclin1 
which inhibits its ability to promote autophagy (239). Formation of the autophagosome is 
negatively regulated by p38-MAPK, as inhibition of the p38 pathway promotes 
autophagic cell death (97, 252). This is thought to be through p38’s interaction with p38-
interacting protein (p38IP) and inhibition of ATG9 trafficking (240). Interestingly, p38 
phosphorylation decreases with cell starvation, and p38IP has less binding affinity to 
dephosphorylated p38 favoring the interaction of p38IP and ATG9 allowing for 
trafficking to the autophagosome and autophagy in starved conditions (240). ERK1/2 
modulates mTOR signalling through TSC1/2 inactivation thereby preventing autophagy 
(132). However ERK also activates Beclin-1, which may be important in promoting the 
later processes of autophagy if they are reached (238) 
Important in the study of autophagy following changes to a cellular environment 
are markers of autophagy. A common marker of autophagy is the conversion of LC3-I to 
LC3-II. This conversion is associated with autophagy, and is proportional to 
autophagosome formation, and is useful as a marker of autophagy,  although it gives no 
details about flux through autophagy (91, 224). Thus in response to a treatment, 
measurement of LC3-I and LC3-II can give insight into the activation of autophagy. 
1.4.3 - Autophagy in Skeletal Muscle and in Muscle Regeneration: 
Autophagy is important in the maintenance of muscle mass and the remodelling 
processes following stress placed on muscle. Stress can occur in situations of nutrient 
deprivation, exercise and disuse (159, 231). Inhibition of autophagy promotes profound 
muscle atrophy with accumulation of abnormal organelles and aberrant structures, and 
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in response to denervation, its inhibition intensified the atrophying of muscle and the 
buildup of abnormal organelles within muscle (137, 158, 230). Additionally, overactive 
autophagy in muscle leads to the development of myopathies and muscle loss (231).  
AMPK activation increases autophagy in C2C12 myoblasts and myotubes 
through mTOR, ULK1 and FoxO3 activation promoting autophagy related gene 
expression (201, 228). Endurance training stimulates autophagy in healthy skeletal 
muscle and without a functioning autophagy system, there is an increase in muscle 
wasting following submaximal exercise (65) . Following exhaustive endurance exercise 
there is an increase in AMPK and ULK1 activation, decease in AKT activation, and an 
increase in autophagy(165). Resistance exercise can also promote autophagy, through 
downregulation of AKT activation, upregulation of AMPK activation and FoxO3 
activation(131). Together this shows that autophagy within muscle is important in 
cellular remodelling as part of adaptation process and to ensure proper muscle 
maintenance. 
In terms of regeneration, declines in autophagy, such as with aging, are 
associated with senescence and a lack of satellite cell mediated regeneration. However, 
reestablishment of autophagy in these cells allows for  regeneration to occur (58). One 
study reported that autophagy promotes satellite cell activation, and inhibition of 
autophagy prevents satellite cell activation (223). Autophagy is activated following the 
induction of differentiation in myoblasts and its inhibition prevents differentiation and 
fusion (51), thereby indicating autophagy as an important contributor to the correct 
execution of differentiation. This same study found that mTORC1 remains elevated 
throughout differentiation and thus autophagy in myoblasts is mTORC1 inactivation-
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independent and inhibition of mTORC1 further stimulated autophagy and impaired 
myotube formation (51). Another study found that over active autophagy during 
myogenesis induces an accumulation of cell-death signalling components which may 
trigger apoptosis and prevent regeneration (128). Since autophagy is sensitive to 
metabolic changes within the cell, the increasing mitochondrial content associated with 
differentiation may explain the increases in autophagy during the transition between 
myoblast and myotube (52). Suppression of autophagy interferes with differentiation, 
proper mitophagy, and the ability of cells to create a mitochondrial network in myotubes 
(215). It is clear that mechanisms are in place to regulate autophagy and that autophagy 
is required for proper myogenesis, which may in part be regulated by the mitochondria. 
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1.5 - Electrical Stimulation: 
Methods have been developed to analyze the effect of exercise on muscle cells 
in-vitro and in-vivo. Electrical stimulation (ES) is a commonly used model, as electrical 
stimulation excites muscle cells as if an action potential from a motor neuron was doing 
so. Initially, ES was utilized to investigate muscle metabolism and training adaptations 
at a cellular level in fully differentiated myotubes (35). More recently however, electrical 
stimulation has been studied with respect to the response of proliferating and 
differentiating myoblasts. Our lab has previously found that in proliferating myoblasts, 
long term (5day) ES elicited Ca2+-dependant-AMPK-mediated cell cycle arrest 
accompanied by an increase in p27T198 and cyclin E bound to p27, which together 
promotes cell cycle arrest (44). In addition, our lab has looked at the effects of ES on 
rhabdomyosarcoma (RMS) cells and found that long term stimulation induces G2 cell 
cycle arrest as well as activation of the autophagy regulator LC3-II (10). This was found 
with an associated increase in AKT activation and a decrease in pAMPK and total p27 
protein levels within proliferating cells (10). Thus, it seems that ES has the ability to alter 
the proliferative capacity of myogenic cells, and may act as a method of inducing altered 
activity within a cell. This altered activity can be used to elucidate mechanisms involved 
in normal myoblast proliferation and differentiation as well as develop interventions for 
satellite cell mediated regeneration of damaged muscle. 
 
 
 
35 
 
2.0 - Study Rationale: 
Previous data from our lab suggests that long term (1-5 days) ES affects 
proliferating C2C12 myoblasts in-vitro, by promoting cell cycle arrest and the induction 
of premature differentiation. Many important adaptations in skeletal muscle occur in the 
recovery period following use and stimulation, however, no experiments to date have 
investigated the early signalling mechanisms involved in ES-induced reductions in cell 
number in proliferating C2C12 myoblasts. Thus, the purpose of this study was to 
examine the early signalling events which lead to the observed reduction in cell number 
seen with long term-ES. This research aims to understand how this altered signalling in 
proliferating myoblasts affects the natural myogenic program and leads to the prolonged 
effects of ES-myoblasts previously investigated. 
 
3.0 - Hypotheses: 
The treatment of proliferating C2C12 myoblasts with one bout of electrical stimulation 
(ES) will: 
1. Alter intracellular signalling in the post-ES recovery period that promotes cell 
cycle exit and cellular remodelling. 
 
2. Alter the normal myogenic program 
 
3. Promote autophagy and cellular remodelling of C2C12 myoblasts. 
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4.1 – Abstract: 
Long term skeletal muscle maintenance requires the activation of quiescent 
satellite cells in order to enter the cell cycle, proliferate to increase cell number, exit the 
cell cycle and subsequently fuse and mature into multinucleated muscle fibres. 
Regulation of this process involves the ordered expression of myogenic regulatory 
factors and cell cycle proteins. Appropriate signalling is important in the maintenance of 
healthy muscle tissue. Electrical stimulation (ES) is a method commonly employed to 
elicit adaptations in muscle, both in-vitro and in-vivo. Recently, ES was shown to 
promote cell cycle arrest in proliferating myoblasts. Our lab has focused on the long 
term effects of ES, but no research to date has focused on the immediate response of 
these cells to stimulation. Thus, we have employed a model whereby proliferating 
myoblasts are subjected to ES for 4hr/day followed by a recovery period. ES induced 
increases in AKT and p42/p44-MAPK activation, as well as an immediate increase in 
AMPK activation. Furthermore total p27 protein levels were reduced in response to ES, 
however p27T198 was stable in the post-ES period. p27T198 was localized predominantly 
within the cytoplasm and ES promoted its nuclear translocation, indicating p27s nuclear 
localization may regulate ES-induced cell cycle arrest. Stimulation reduced both p38 
and Mef2A protein levels, with no changes in myogenin indicating that the differentiation 
capacity of these cells may be compromised. Interestingly, there was an immediate 
upregulation of autophagy marker LC3II, which was subsequently diminished by 16 
hours post-ES. Together our results indicate that cell cycle withdrawal and autophagy 
mediated cellular remodelling occur in the response of proliferating myoblasts to ES.  
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4.2 - Introduction: 
 Skeletal muscle makes up approximately 40% of human body mass and its 
primary function include ambulation and metabolism. The ability to maintain and 
regenerate muscle mass following injury and replenishing myonuclei as they senesce 
are vitally important in ensuring health across the lifespan. Situations that arise in which 
the regenerative capacity of muscle is hindered have negative ramifications on overall 
maintenance and homeostasis of skeletal muscle. Since skeletal muscle is being 
identified as a major contributor to overall health, an understanding of the initiation and 
regulation of the regenerative process is important for the development of interventions 
to maintain the regenerative capacity of muscle and overall muscle health. 
 Maintenance of skeletal muscle mass is largely controlled by satellite cells (SCs; 
147, 201), which lie between the sarcolemma and basal lamina of muscle fibres (74, 
139). These SCs are important in both muscle regeneration and adaptation to exercise 
(39, 85, 194). The first step in SC response to injury is exit from quiescence and entry 
into the cell cycle. Once the appropriate cell numbers have been reached, the cells 
must exit the cell cycle prior to differentiation, a necessary step for the fusion into the 
damaged muscle fibre (74).  
Cell cycle arrest in muscle is thought to be controlled mainly by MyoD which 
promotes the expression of cell cycle inhibitor p21 leading to cell cycle arrest (67, 70, 
102, 216, 218, 227, 256, 259). However other cell cycle inhibitors such as p27 and p57 
have been implicated in myogenic cell cycle control as well (29, 32, 141, 189, 255, 260). 
Electrical stimulation (ES) has been used as a method of altering the intracellular 
signalling within muscle both in-vitro and in-vivo (10, 35, 41, 44). Our lab has previously 
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demonstrated that in proliferating myoblasts long term (5 day) ES elicits Ca2+-
dependant-AMPK-mediated cell cycle arrest, accompanied by an increase in p27T198 
and cyclin E bound to p27. We have also shown that ES of rhabdomyosarcoma (RMS) 
cells induces G2 cell cycle arrest and activation of autophagy. 
The induction of the basic helix loop helix (bHLH) family of myogenic regulatory 
factor (MRF) expression in myoblasts following SC activation promotes muscle specific 
gene expression regeneration (14, 15, 199, 249). Primary MRFs, MyoD and Myf5, 
promote muscle lineage specification and cell cycle arrest, whereas secondary MRFs, 
myogenin and MRF-4, promote differentiation of myoblasts into muscle(181). There is 
overlapping expression  and temporal activity of the MRFs, which orchestrate 
myogenesis (14, 181). Mice deficient in both MyoD and Myf-5 display a lack of 
myoblasts and mature muscle (21, 196), but MyoD-/- mice display a compensatory 
increase in Myf-5, whereas MyoD does not compensate for in Myf-5-/- mice (21). 
Myogenin is necessary for muscle formation and development whereas MRF-4 may be 
dispensable  (41, 73, 151, 261). Further, differentiation is enhanced by the  MAD box 
transcription factors, myocyte enhancer factors 2 (MEF2) proteins (18, 244, 254). The 
promoter region of many muscle specific genes are responsive to both MEF2 and MRF 
binding (63, 136, 178, 179, 199), and a synergistic and co-operative action between the 
two families of proteins exists (31, 45, 148, 153). We have shown previously that ES of 
proliferating C2C12 myoblasts induces increases my MyoD protein but reduces 
myogenin protein content (44). However both are necessary for normal skeletal muscle 
formation and the SCs response to muscle injury (44). 
Based on this evidence we subjected proliferating C2C12 myoblasts to one bout 
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of ES to determine what the immediate early signalling events are that induce the long 
term response to ES. We show that following 4 hours of ES there is a significant 
reduction in cell number, with immediate and maintained activation of AKT and ERK1/2, 
while AMPK activation diminishes during recovery. Cell cycle inhibitor p27 levels were 
reduced following ES, but p27T198 was unchanged and greater within the cytoplasmic 
fractions of myoblasts, although a shift towards nuclear localization occurred in 
response to ES. Furthermore, LC3II, a marker of autophagy, was elevated immediately 
following ES, but returned to control levels late in the post-ES recovery period. Overall 
our results suggest that ES alters intracellular mechanisms involved in proliferating 
myoblasts, halting proliferation in what may be a p27 mediated-pathway. ES may also 
be promoting autophagy regulated cellular remodelling. These results may explain the 
effects of long-term ES on C2C12 proliferation and the potential role of ES in muscle 
regeneration. 
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4.3 - Materials and Methods: 
Cell Culture 
C2C12 myoblasts (ATCC, Manassas, VA) were maintained at 37oC and 5% CO2, in 
high glucose Dulbecco’s Modified Eagle Medium (DMEM; Wisent, St. Bruno, QC), 10% 
Fetal Bovine Serum (FBS; Hyclone, Thermo Fisher Scientific, Whitby, ON), and 3% 
Anti-micotic/Anti-biotic (Wisent). Media was replenished every 48 hours in necessary 
experiments. Prior to plating, 6 well culture plates were coated in 0.1% gelatin and 
exposed to UV light for 40 minutes. 
Electrical Stimulation 
Cells were stimulated (10V, 5Hz, 2ms delay, alternating current direction) using a 
Harvard Apparatus Stimulator CS System (Harvard Apparatus Canada, Saint-Laurent, 
QC) for 4 hours/day for 1 day. Control cells were plated and collected at the same time 
as stimulated cells. Collection took place at various time points following the cessation 
of stimulation. The lids of the plates were fitted with two parallel platinum wire 
electrodes extending into the media and were connected to a cell culture stimulator. 
Prior to stimulation, media was added to create a total volume of 4mL to allow the 
electrodes to contact the media. 
Cell Harvesting 
Throughout the post stimulation recovery period cells were harvested. Media was 
removed, and cells were washed twice with cold Phosphate Buffer Saline. Cells were 
subsequently collected centrifuged at 2,100 xg at 4oC.  The pellet was resuspended in 
TENT buffer solution (0.2% TENT – TRIS, EDTA, NaCl, 0.2% Triton x-100) 
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supplemented with 1% protease inhibitor (Sigma, Oakville, ON), and 1% phosphatase 
inhibitor (Roche Diagnostics, Indianapolis, IN). The cells were then sonicated for 3 
seconds and centrifuged at 16,100 xg at 4oC. The supernatant lysate was then removed 
and stored at -84oC for later analysis. 
Cellular Fractionation 
Media was removed from the cells and were washed twice in warm PBS. Cells were 
harvested by trypsinization, and cells were washed with cold PBS and centrifuged at 
2,100 xg at 4oC. The pellet was resuspended in 100 l of a 1x TEN isotonic transport 
buffer. Digitonin (BioVision, Milpitas, CA; 20-30g/ml final concentration) was used to 
permeabilize the plasma membrane until 90-95% of cells exhibited trypan blue staining. 
When 90-95% of the cells exhibited trypan blue staining, the samples were centrifuged 
at 2,100 xg and the supernatant was collected. This supernatant represents the 
cytoplasmic fraction. The pellet represents the nuclear fraction and was resuspended in 
100 l of 1XTEN, sonicated, and subsequently centrifuged for 10 minutes at 16,100 xg. 
The cellular fractions where then stored at -84oC for later analysis. 
Immunoblotting 
 Protein concentrations within samples were determined by a Bradford Assay. 25 
μg protein /lane was loaded into onto a 12 or 15% SDS-PAGE gel and run at 120V for 
90-120minutes. Separated proteins were subsequently transferred onto a PVDF 
membrane (Bio-Rad, Mississauga, ON) overnight at 40V. Membranes were then 
stained in amido black and blocked in 10% milk for 2 hours. Contents of the western 
blot were subsequently probed for using primary antibodies overnight at 4oC for: AMPK, 
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p-AMPKT172, AKT, p-AKTT308, p-AKTs473, p42-MAPK, p44-MAPK, p-p42-MAPK, p-p44-
MAPK, GSK-3β, pGSK-3βS9, LC3, RCC1 (Cell Signaling, Danvers, MA), Mef2A, Mef2D, 
p38, p-p38, p27 (BD Biosciences, Mississauga, ON), t198-p27 (R&D Systems, 
Minneapolis, CA), Myogenin and β-Actin (Abcam, Cambridge, MA).Following 
incubation, membranes were washed 3 times for in Tris-Buffer Saline with Tween 
(TBST) and subsequently placed in anti-mouse and anti-rabbit HPR-linked secondary 
antibodies (Santa Cruz Biotech, Santa Cruz, CA) with 5% milk for 1 hour. Proteins were 
visualized using immobilon enhanced chemiluminescence substrate (Millipore, Whitby, 
ON) and detected or quantified on a Kodak In Vivo FX Pro Imager (Marketlink Scientific, 
Burlington, ON) using Carestream software. Protein loading was corrected using β-
Actin. 
Statistical Analyses 
 All statistical analyses were performed using GraphPad Prism 5 software. 
Unpaired student’s t-tests were performed to determine if there were any statistical 
significance between control and stimulated conditions at a given time point. Statistical 
significance was found in any comparisons when differences between the means 
reached p<0.05. One-way ANOVAs were conducted to determine the effect of 
ES/Control, and statistical significance was found when p<0.05. 
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4.4 – Results: 
Electrical stimulation reduced cell number 
 Immediately following ES there seems to be no difference in cell count between 
control and stimulated myoblasts, however by 16 hours post-stimulation there is a 
dramatic difference in cell number in control compared to stimulated myoblasts, 
whereby the control cells are reaching confluence, and the ES-treated cells are not 
(Figure 9). 
 
 
Figure 9: Electrical stimulation reduced cell number by 16 hours post-ES in comparison 
to time matched controls. Top are representative photos of non-stimulated myoblasts. 
Bottom are representative photos of ES-treated myoblasts. 
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Electrical stimulation activates cell signalling during recovery 
Immediately following ES there was a 1.4-fold increase in pAMPKT172 in 
comparison to control, which had a peak 2.1-fold increase above control at 4 hours 
post-ES. pAMPKT172 then declined to pre-ES levels by 6 hours post-ES (Figure 10A,B). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Electrical stimulation (ES) of proliferating C2C12 myoblasts induced 
early AMPK phosphorylation in comparison to non-stimulated cells. Immediately 
following ES AMPK phosphorylation was increased, followed by a normalization 
of phosphorylation to time matched control levels late in the recovery period (B). 
All values are mean ± S.E.M.; * p<0.05 compared to time matched controls (n=4-
6). 
 
 Since AKT is important in skeletal muscle proliferation and differentiation, we 
analyzed pathway activation following ES. ES elicited an immediate 2.6-fold increase in 
pAKTT308 which reached a maximal 5.5-fold increase at 4 hours post-ES compared to 
non-stimulated control cells. pAKTT308 levels declined for the remainder of the recovery 
period, eventually reaching pre-ES levels after 20 hours (Figure 11A,B). Unlike 
pAKTT308, ES caused no increase in pAKTS473 phosphorylation immediately after the 
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cessation of stimulation (Figure 11A,C). pAKTS473 levels rose during the recovery period 
and reached a significantly greater levels 2 hours after stimulation, and a peak 2.4-fold 
increase in comparison to non-stimulated controls 4 hours post-ES. Subsequently, 
pAKTS473 levels rapidly declined, reaching control levels throughout the remainder of the 
recovery period (Figure 11A,C). 
 AKT phosphorylates GSK-3β on S9 and this inhibitory phosphorylation alleviates 
GSK-3βs repression on myogenin, which in turn promotes differentiation. Despite 
activating AKT, ES did not lead to GSK-3β phosphorylation (Figure 12A,B). However, 
there is a trend towards increased GSK-3β phosphorylation between 4 and 20 hours of 
recovery (p=0.10). No changes in myogenin protein levels were evident at any time 
point throughout the experimental protocol (Figure 12A,C). 
 Mitogen activated protein kinases (MAPKs) play an important role in skeletal 
muscle signalling and myogenesis, thus we evaluated the effects of ES on p42 and p44 
MAPK. ES induced a rapid phosphorylation of both p42 and p44, being 2.5-fold and 2.2-
fold greater in stimulated cells than control, respectively (Figure 13A-C). The two 
MAPKs appear to respond differently throughout the post-ES recovery period. p42-
MAPK phosphorylation appears to dip towards the levels seen in control cells shortly 
after the cessation of stimulation, but rises to levels that were 2.4-fold above control by 
20 hours post-ES (Figure 13A,B). In contrast, p44-MAPK phosphorylation is elevated 
2.5-fold following ES and appears to be decreasing throughout the recovery period 
(Figure 13A,C), although elevated above control 16 hours post-ES. 
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Figure 11: Electrical stimulation (ES) of proliferating C2C12 myoblasts increased 
pAKTT308 and pAKTs473.  pAKTT308 was significantly increased immediately after 
ES and declined following 4 hours post-ES in comparison to time matched 
controls (B). pAKTS473 was significantly elevated by 2 hours post-ES and 
remained elevated throughout the recovery period in comparison to time 
matched controls (C). All values are mean ± S.E.M.; * p<0.05 compared to time 
matched controls (n=4-6). 
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Figure 12: p-GSK-3βS9 and myogenin protein are unchanged following electrical 
stimulation (ES) in comparison to time matched control cells (C). GSK-3β was 
not phosphorylated more in ES cells compared C cells, although an increasing 
trend was evident late in the recovery period (B). Myogenin protein content did 
not change post-ES, nor was it different than C (C). All values are mean ± 
S.E.M.; * p<0.05 compared to time matched controls (n=4-6). 
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Figure 13: Electrical stimulation (ES) promoted p42 and p44- MAPK 
phosphorylation, although the response following ES differed. p42-MAPK 
phosphorylation was greater in ES than C treated myoblasts immediately 
following stimulation, and not-significantly greater until late in the recovery period 
(B). p44-MAPK phosphorylation was greater in ES than C treated cells 
immediately following stimulation, and remained elevated until 20hours post-ES 
(C). All values are mean ± S.E.M.; * p<0.05 compared to time matched controls 
(n=4-6). 
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Electrical stimulation may alter the differentiation capacity of proliferating C2C12 
myoblasts 
 p38-MAPK is important in promoting differentiation through phosphorylating and 
subsequently activating Mef2A-D. Following ES there was a 41% reduction in total p38 
protein content, and this was maintained throughout the recovery period (Figure 14A,B). 
Phosphorylated p38 was not detected at any time points following stimulation. (Figure 
14A). MEF2A and D protein content was measured, as they are integral for the muscle 
differentiation process, and have the ability to be activated by p38. MEF2A protein 
content was significantly reduced by 40% immediately following ES. MEF2A levels 
began to rise, reaching control levels between 2 and 6 hours post ES. Following this, 
MEF2A levels declined by 57.2% less than those in controls by 20 hours post 
stimulation, the lowest value in the recovery period (Figure 14A,B). In contrast, Mef2D 
protein content is not changed in response to ES (Figure 14A,C). 
p27T198 is a stable form of p27 in response to electrical stimulation 
 In response to ES, there is a reduced cell count, which could be due to cell death 
or cell cycle arrest. Furthermore, p27 is a target of both AMPK and AKT following their 
activation, and thus p27 was measured to determine if it was responsible for the 
reduced cell count in response to ES. Immediately following ES, p27 protein levels were 
reduced by more than 55% compared to non-stimulated control cells (Figure 15A,B). 
This reduction was maintained through the entire post-ES recovery period. Given that 
AMPK was increased immediately following ES in comparison to control cells, we 
measured p27T198, and found that its protein levels were unchanged throughout the 
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post-ES recovery period (Figure 15A,C). Thus, when expressed relative to total p27, the 
relative amount of p27T198 was anywhere between 1.87-fold and 3.49-fold greater in ES 
cells than time matched controls following ES and the recovery period (Figure 15D). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Electrical stimulation (ES) of proliferating C2C12 myoblasts reduced 
p38-MAPK and MEF2A protein content and MEF2D protein remained 
unchanged. p38-MAPK protein content was reduced following ES in comparison 
to time matched control cells (A). MEF2A protein content was reduced following 
ES and increased to control levels throughout the recovery period followed by a 
decrease in comparison to control (C). MEF2D protein levels in ES-cells did not 
change throughout the recovery period versus time matched controls (D) All 
values are mean ± S.E.M.; * p<0.05 compared to time matched controls (n=4-6). 
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 We were surprised that total p27 decreased in cells post-ES given the large loss 
in cell number. To further explore the p27 response to 4 hours of ES we determined that 
total p27 accumulation was in the nucleus in non-stimulated cells (90%) and ES 
increased this to 95%, coming back to control levels of 90% 20 hours post-ES (Figure 
16A,B). In contrast, majority of the p27T198 accumulated in the cytoplasm of these cells 
(Figure 16A,C). However, ES caused 22% of the p27T198 protein to be located within the 
nucleus, while 6 hours-post ES 39% of the protein was located in the nucleus, which 
amounts to an 80% increase in nuclear p27T198 6 hours post-ES. Nuclear levels were 
subsequently reduced to 26% after 20 hours (Figure 16A,B). Furthermore, to ensure the 
nuclear integrity of the fractioned cells was not compromised by digitonin treatment, we 
measured RCC1, a nuclear protein, and determined that we had only permeabilized the 
plasma membrane (Figure 16A). Amido black staining of the PVDF membrane was 
conducted to confirm that nuclear and cytoplasmic fraction compositions differed (Figure 
16A). 
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Figure 15: Electrical stimulation (ES) reduced p27 protein levels and increased 
the relative phosphorylation of p27on the T198 residue. p27 protein levels were 
reduced following stimulation in comparison to time matched control (B) T198 
phosphorylation of p27 was unchanged following stimulation (C). The relative 
amount of p27 that was phosphorylated on the T198 residue was greater 
following ES than in time matched controls (D). All values are mean ± S.E.M.; * 
p<0.05 compared to time matched controls (n=4-6). 
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Figure 16: p27 was localized within the nucleus of proliferating C2C12 
myoblasts, whereas p27T198 was localized within the cytoplasm of proliferating 
C2C12 myoblasts in both control and ES conditions. Total p27 within the nucleus 
increased in response to ES, p27T198 increased within the nucleus of cells in 
response to ES (B). All values are mean ± S.E.M.; *p<0.05 (n=3). 
 
Electrical stimulation immediately activates but does not maintain autophagy 
 ES led to a reduced cell count in comparison to control cells. This could be due 
to autophagy, which can promote cell cycle arrest and cell death. Furthermore 
autophagy can be positively regulated by AMPK and negatively regulated by AKT. As 
an indicator of autophagy we measured the conversion of LC3I to LC3II following ES, as 
LC3II levels are proportional to autophagosome formation and is a common marker of 
autophagy. Following ES there is a 2.6-fold increase in LC3II, with a peak 4.5-fold 
increase in LC3II evident at 2 hours post-ES (Figure 17A,B). Interestingly, this was 
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followed by a reduction in LC3II and a return to levels similar to those seen in non-
stimulated control cells by 16 hours of recovery (Figure 17A,B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Immediately following stimulation there was an increase conversion of 
LC3I to LC3II that was normalized late in the recovery period. Stimulation 
increased LCII/LC3I in comparison to time matched controls immediately 
following stimulation and this was normalized to control levels by 16 hours post-
ES (B). All values are mean ± S.E.M.; * p<0.05 compared to time matched 
controls (n=4-6). 
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4.5 - Discussion: 
 Electrical stimulation (ES) is a method commonly employed to induce 
intracellular changes within cells (10, 35, 41, 44). It has the ability to promote changes 
within C2C12 myoblasts that may alter the development of these cells into functional 
myotubes. It also provides insight into the importance of regulated signalling within 
myoblasts. No work to date has focused on the immediate early responses of 
proliferating myoblasts to ES. Thus the goal of this work was to investigate early 
signalling within these ES-cells and evaluate the effects of any changes on C2C12 
proliferation.  
ES of myoblasts causes a reduction in cell number. This result can be due to cell 
cycle exit or cell death. Previous work has shown that long term ES (3-5 days) of 
proliferating myoblasts promotes AMPK-mediated cell cycle exit by increasing p27 and 
MyoD, mediated by increases in intracellular Ca2+ (44). However, this reduction in cell 
number could also be due to increases in programmed cell death, such as that seen 
with prolonged autophagy (118). No increases in autophagy activity were evident after 2 
and 4 days of ES (Appendix 1, Figure 20), suggesting that long term ES does not 
increase autophagy. However, immediately following ES the situation is very different. 
AMPK is activated in response to 4 hours of ES and this was accompanied by an 
increase in LC3II (Figure 10B and 17B), although LC3II returns to pre-ES levels during 
the recovery period, a response similar to AMPK. LC3II is not increasing long term, 
which is in contrast to what is observed in rhabdomyosarcoma (RMS) cells, which 
express many of the same myogenic proteins, whereby LC3II is elevated by long-term 
stimulation (10). This may be due to the transient upregulation in AMPK activity which 
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promotes the early autophagy (68, 83, 100), while the sustained AKT activation leads to 
the suppression of autophagy, possibly through Beclin-1 and mTOR (69, 239). Overall it 
appears AMPK may increase autophagy post-ES, which acts as a remodelling process 
within these cells, however, AKT overrides this in the long term (Appendix 1, Figure 19; 
10), different from the proposed autophagy induced cell death seen in RMS cells (10).  
ES activates AMPK immediately following treatment and decreases late in the 
recovery from ES. AMPK activation increases after 5 days of ES treatment, suggesting 
that AMPK activation in response to long term ES may be a cumulative response, 
building upon itself day by day. Furthermore, AMPK has the ability to promote cell cycle 
exit in C2C12 myoblasts through phosphorylation of p27 on T198 in response to ES 
(44), which represents a possible mechanism for the reduced number of cells following 
ES. Interestingly 1 bout of ES reduced total p27 protein content, which is contradictory 
to promotion of cell cycle withdrawal (29, 141). p27T198 appears to be resistant to this 
ES-induced effect given that p27T198 is unchanged following 4 hours of ES, which 
agrees with previous research on the stability of p27T198 in response induced total p27 
degradation  (106, 203). We show that the majority of p27 is nuclear and yet 
surprisingly, p27T198 is highly cytoplasmic (113). There appears to be an increase in 
nuclear total p27 immediately following stimulation and the reduction in total cell p27 
suggests that there is a decline within the cytoplasmic fraction. This is also suggested 
by the increase in nuclear p27T198 during the recovery phase, suggesting a possible 
p27T198 translocation. This translocation may represent an important step in shutting off 
proliferation in C2C12 myoblasts following ES. Since ES allows p27 to bind cyclin E 
more readily in myoblasts (44), p27T198 may have increased affinity for cyclins and this 
58 
 
phosphorylation may be highly important in cyclin/CDK inhibition and cell cycle arrest in 
response to ES.  
 Activation of AKT has been linked to the regulation of both muscle proliferation 
and differentiation. AKT has the ability to promote proliferation by preventing p27 
nuclear import via T157 phosphorylation (122) and inhibiting FOXO transcription factors 
which increase the expression of p27 and reduce cyclin D levels (22, 30, 105, 133, 204, 
214). However, ES-dependent AKT activation does not appear to be enhancing 
proliferation, as indicated by the reduced number of cells in response to long term ES 
(44). Rather, AKT may be exhibiting its pro-differentiation effects due to an apparent 
late trending increase in GSK-3β phosphorylation and thus inactivation. This may be 
promoting differentiation by alleviating its repression on myogenin, which is necessary 
for skeletal muscle fibre formation (188), although these effects on myogenin are not 
evident by 20 hours post-ES. Long term stimulation may result in significant increases in 
GSK-3β phosphorylation like those found previously in a rhabdomyosarcoma (RMS) 
cells (41) and promote differentiation in ES-treated proliferating myoblasts. 
Active p38-MAPK is important in slowing proliferation and promoting 
differentiation as is it activates MEF2A and MEF2C directly (162, 262) and inhibits cyclin 
D indirectly (2, 116, 226). Interestingly, ES induced a reduction in p38 protein content, 
while phosphorylated p38 was undetected by western blot. Since p38 is activated upon 
mitogen-depletion to promote differentiation (23, 245), the lack of p38 phosphorylation 
suggests that differentiation was not being properly being induced by ES. Furthermore, 
the reduction in total p38 in response to ES suggests a reduction in the pathway 
capacity and may have negative ramifications on the ability of these cells to differentiate 
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by decreasing p38 activation of MEF2s (8). MEF2A has been shown to be essential in 
myoblast differentiation and muscle regeneration, whereas MEF2 B, C, and D are not 
(47, 207). The decline we see in MEF2A in response to ES may further limit terminal 
differentiation. Thus, although ES appears to be ceasing proliferation, it may limit the 
differentiation capacity of the myoblasts and may explain why long term ES appears to 
induce premature differentiation (44) 
 Our results indicate that ES causes multiple changes in intracellular signalling 
within proliferating C2C12 myoblasts, promoting premature cell cycle withdrawal and 
autophagy mediated cellular remodelling. This may have ramifications in muscle 
maintenance, whereby activation of a satellite cell prior to or during cell fusion with 
existing muscle fibres, may impair proper repair of injury or myonuclei renewal. 
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5.0 – Overall Conclusions: 
 Satellite cells serve as proliferative-capable muscle precursor cells that give rise 
to myoblasts following their activation and exist on the periphery of myofibres. Following 
muscle injury there is an activation of satellite cells, which proliferate and subsequently 
differentiate, donating their nucleus to the injured muscle, a vital step in regeneration. 
Numerous approaches exist to explore the molecular mechanisms involved in the 
muscle regeneration process. We employee an electrical stimulation (ES) model as a 
method of altering the signalling within proliferating C2C12 myoblasts to further 
understand the mechanisms involved in myoregeneration. We can then investigate the 
early signalling response of proliferating myoblasts following exposure to ES and better 
understand how electrical stimulation of myoblasts affects regenerative capacity.  
There is a reduction in proliferation of C2C12 myoblasts following as little as one 
4 hour bout of ES, as evident by the reduction in cell numbers. This was accompanied 
by long term morphological changes, whereby myoblasts align in a fashion that 
suggested that like they were preparing to fuse and differentiate (44). This cell cycle 
arrest may occur prior to the G1/S transition due to increases in p27 binding to cyclin E 
(44). My thesis was designed to examine the immediate response of proliferating 
C2C12 myoblasts to 1 bout of ES in aims of understanding the long term effects that are 
promoted by ES-treatment. 
The AMPK, AKT and MAPK signalling pathways have diverse roles in the 
processes of proliferation and differentiation, and all have been shown to affect the cell 
cycle and myogenesis. They have observed differential effects by acting on proliferation 
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in a sub-confluent state and differentiation following confluence and mitogen depletion 
(30, 79, 103, 245). The alterations in the activation of these proteins have the ability to 
promote changes in the developmental program within these myoblasts. Thus, the 
changes seen in response to ES have the potential to affect both proliferation and 
differentiation within these myoblasts. My observations suggest that the forced 
activation of these proteins by ES act in a manner to promote cell survival and prevent 
cell division, and it appears that ES decrease the differentiation capacity of these cells. 
ERK1 and 2 respond differently to ES, indicating that although closely related, 
the ERKs respond uniquely to ES. Interestingly, ERK1/2 can promote both proliferation 
and differentiation, however its inactivation is necessary for the transition from 
proliferation to differentiation (1, 64, 78, 88, 144, 163, 222). Thus ES may be 
prematurely activating ERK1/2 and promoting differentiation or ES may be inducing 
changes in ERK1/2 localization from the nucleus where it induces proliferation, to the 
cytoplasm where it is associated with differentiation (136). Whether this shift in ERK1/2 
localization occurs warrants further investigation. 
It appears that ES is inducing a targeted degradation of specific proteins within 
the cell. Furthermore, the phosphorylation of AMPK, AKT and p27 seems to prevent 
their breakdown, suggesting these phosphorylations are important in stability of the 
protein, agreeing with previous work (48, 106, 203). Additionally, total p38 and MEF2A 
are reduced, and phosphorylation of these proteins was not detected or measured. 
Thus, no phosphorylation induced stability effects can be inferred. This raises the 
question of whether the relative or absolute activation of these proteins is important for 
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intracellular signalling. My work suggests that the relative activation is important in 
terms of AKT and p27, as the downstream targets are activated in response to ES. 
In response to low energy conditions and cellular stress, autophagy can be 
activated in aims of returning cellular energy balance. It does so through organelle 
breakdown and recycling intracellular components, and in further promotes cell cycle 
arrest (124). Autophagy functions in cellular remodelling, such as with the mitochondria 
and mitophagy, in response to exercise-induced stress and disuse/denervation induced 
stress (26, 87, 92, 230, 231). This promotes destruction of dysfunctional mitochondria 
and it may be similar to what we observe, albeit at an individual cellular level. Excessive 
degradation of intracellular components by autophagy has been linked to cell death 
(118). In response to ES, there is an immediate increase in autophagy followed by a 
normalization to control levels. Thus deficient cells may undergo autophagy, indicating 
that autophagy may be promoting cellular “pruning” in response to ES. This immediate 
response in C2C12 cells is similar to what is observed following long term ES in 
rhabdomyosarcoma cells (10). However, long term-ES does not induce prolonged 
activation of autophagy, suggesting that despite both cell types expressing muscle-
specific proteins, their adaptation to ES is very different. 
The observed reduction in cell number, lack of long term autophagy, and the 
increased stability of p27T198 following ES lead to further investigation of p27 as a 
regulator of ES-induced cell cycle arrest. Specifically, I wanted to investigate where p27 
is localized, and if the reductions in p27 were localization specific in response to ES. 
Reductions in total p27 seem to be in the nuclear fraction of the myoblasts, whereas 
p27T198 accumulates within the nuclei and cytoplasm of these cells. Thus, it seems that 
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p27T198 drives the cell cycle arrest in ES-myoblasts, potentially due to enhanced nuclear 
import of p27T198 or greater binding affinity for the cyclins to promote cell cycle arrest 
(Figure 18), similar to the finding that p27 binds cyclin E following long-term ES 
promoting cell cycle arrest. 
Overall the change in observable characteristic elicited by ES within proliferating 
myoblasts underlies the importance of coordinated signalling within C2C12 myoblasts in 
terms of myogenesis and muscle regeneration. ES may in fact be a hindrance to 
effective therapy following muscle damage, as it may limit the proliferative and 
differentiation capacity of the activated satellite cells, thereby preventing the necessary 
donation of muscle progenitors to the damaged muscle fibre. However, this does not 
leave out the possibility of using ES as method of aiding in the differentiation process, 
which would require proper timing in response to muscle damage. Stimulation too early 
may hinder proliferation, whereas if timed appropriately may enhance differentiation. 
Further experiments are required to determine the use of ES as a possible therapy 
following muscle damage and in response to muscle wasting or myopathies. 
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Figure 18: Current working model based on data and observations collected. Electrical 
stimulation (ES) promotes intracellular changes within proliferating C2C12 myoblasts. 
Cell cycle arrest is in part mediated by p27. Autophagy is promoted early in the post-ES 
recovery pervious, but autophagy is not withheld, indicating a remodelling of intracellular 
components. Differentiation may be limited following ES due to reductions in p38, 
Mef2A, and a disconnect between AKT, GSK-3and myogenin. 
 
 
 
 
65 
 
6.0 - Limitation and Future Directions: 
6.1 – Limitations: 
 The current work utilized electrical stimulation (ES) as a method of the altering 
signalling within proliferating C2C12 myoblasts. This in-vitro work provides plenty of 
insight into the importance of proper signalling within the development of musculature 
and how dysregulation in signalling affects the normal myogenic program, however in-
vitro work is not always reproducible in an animal model, and thus the results would 
need to be further investigated using an animal model in order to gain insight into the 
true physiological ramifications of ES on skeletal muscle regeneration. Furthermore, I 
use proliferating C2C12 myoblasts as a model cell of post-activated satellite cells, 
however these cells are not satellite cells and despite the similarities, may not respond 
to ES the exact same way that satellite cells do. To investigate the response of ES on 
satellite cells, primary satellite cells would need to be extracted from intact and exposed 
to ES. These limitations do not indicate that using myoblasts in an in-vitro model are not 
appropriate for studying the effects of ES and altered signalling on muscle regeneration. 
However, they pose a constraint on the ability to generalize my findings in a 
physiological setting. 
6.2 - Future Directions: 
 The current work along with previous work answered many of the questions 
proposed in this study. However, it does create new questions to be answered, 
requiring further investigation. 
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6.2.1: Cause of Reduced Cell Count 
 A reduction in the number of myoblasts is evident following ES, yet the reasons 
for this observation are not fully understood. Further experiments are necessary to 
determine whether this reduced cell count in response to ES is mediated through the 
onset of cell cycle arrest, autophagy mediated cell death or increases in apoptosis. 
Apoptotic markers were not measured in the current work. Next steps would include 
measurement of markers such as Bcl-2, AIF, caspase3,6 or,7 or BH3 in response to 
ES. This would provide insight into if apoptosis is occurring and whether it is through a 
caspase-dependent or independent mechanism. Furthermore, only LC3 was used as a 
marker of autophagy. But, to gain insight into whether autophagy is functionally 
increased within these cells, and if it is an immediate response to ES, more markers of 
autophagy must be measured. Examples of this would be Beclin-1, ATG3, ATG7, or any 
complexes formed throughout autophagy. Furthermore, lysosome activity could be 
measured to see if there is flux through the autophagy pathway. 
The results indicate that the reduction in cell count in response to ES is likely due 
to cell cycle effects of ES on myoblasts. In RMS cells ES induced a G2/M cell cycle 
arrest and long term autophagy, and ES induced G1/M cell cycle arrest was suggested 
from previous work done in ES-myoblasts. FACS analysis of ES-myoblasts would 
determine where majority of the cells accumulate within the cell cycle. FACS could 
further direct the research to investigating cycle-specific events that promote cell cycle 
arrest. Furthermore it could provide insight as to whether autophagy or apoptosis is 
taking place depending on if the cells are arrested in G1/S or G2/M. Although ES 
increased the specific levels of p27T198 and it is localized within both the nuclei and 
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cytoplasm of these cells. Other cell cycle inhibitors may also be promoting cell cycle 
arrest in response to ES, such as p21 and p57, and their protein content and activity 
should be measured to determine the role they play in ES-mediated proliferative 
declines. p21 might be of prime interest due to its direct connection with MyoD within 
muscle and ES has been shown to increase MyoD expression in proliferating C2C12 
myoblasts (44). Furthermore, immunoprecipitation of both total and p27T198 with various 
cyclins in whole cell extracts and nuclear and cytoplasmic fractions will determine the 
interactions and cell cycle ramifications of p27T198 within the cytoplasm and nucleus of 
ES-myoblasts. 
6.2.2 – Ramifications of Intracellular Signalling: 
 Widespread intracellular changes were observed after as little as a single 4 hour 
bout of ES, illustrating ES as a powerful tool for inducing phenotypic changes. However 
the downstream effects of these changes have yet to be investigated, and warrant 
further investigation in order to understand the cellular events that take place in 
response to ES and its applications within myogenesis. It is unknown at the present 
time if the AMPK activation is AMP:ATP driven, or Ca2+ driven. However, previous work 
does indicate it is Ca2+ mediated and chelation of [Ca2+]IC will provide necessary insight 
into what is responsible for AMPK activation. Moreover, inactivation of AMPK with 
Compound C could uncover a mechanism by which AMPK alters myoblast proliferative 
capacity in response to ES. 
AKT activation is thought to prevent autophagy and promote cell growth and 
division. However, this is contradictory to what we observed after ES, thus the 
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consequence of AKT activation following ES could be further investigated through AKT 
inhibition, by inhibiting its receptors/activators, using siRNA, or pharmacological 
inhibition. This could provide insight into the role of AKT activation during the C2C12 
myoblast response to ES.  These studies would also allow investigation into the 
dysregulation of the AKT-GSK3β-myogenin axis in response to ES. 
The mitogen sensitive protein kinases (MAPKs) play an integral role in both 
proliferation and differentiation of myoblasts. I show that ERK1/2 are activated in 
response to ES but the ramifications of this activation remain unknown at the present 
time. The diverse roles of these MAPKs within cells were not investigated in the current 
study, although measurements of downstream targets of ERK1/2 could provide insight 
into the roles of p42 and p44 in response to ES. Furthermore, like AKT, ERK1/2 could 
be pharmacologically inhibited or silenced using siRNA’s to investigate the role it plays 
in the ES-response. Cellular localization assays of p42 and p44 would further determine 
the role their location plays in the proliferation and differentiation of myoblasts and the 
consequence of its potential localization change following ES treatment. 
6.2.3 – Differentiation Capacity of ES Myoblasts: 
 The differentiation capacity of myoblasts following ES appears to be 
compromised. To evaluate this, ES-treated cells could be exposed to differentiation 
conditions and any effects on the speed or completeness of differentiation could be 
measured. Such measures could be a fusion index or MHC in comparison to control 
cells. The dramatic reductions in p38 and Mef2A could have negative effects on the 
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differentiation capacity of these cells, although this work could answer the question if 
these cells are capable of differentiation. 
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Appendix 1 – Supplementary Data: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: 2 and 4 days of electrical stimulation (ES) promoted the activation of AKT, 
reductions in myogenin protein content and no activation of AMPK in proliferating 
C2C12 myoblasts (B) AKT was phosphorylated on the T308 residue following 2 days 
but not 4 days of ES in comparison to control. (C) AKT was phosphorylated on the S473 
residue following 2 days but not 4 days of ES in comparison to control. (D) Myogenin 
protein content was reduced by 4 days of ES in comparison to control cells. (E) AMPK 
was not phosphorylated following 2 or 4 days of ES. β-Actin was used as a loading 
control and all values are mean ± S.E.M.; * p<0.05 compared to time matched controls 
(n=4-6). 
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Figure 20: LC3II/LCI protein levels in C2C12 myoblasts was unchanged in response to 
ES. (B) ES and C cells show no difference in the proportion of LC3II to LC3I. β-Actin 
was used as a loading control and all values are mean ± S.E.M.; * p<0.05 compared to 
time matched controls (n=4-5). 
 
AKT is an important signalling molecule within cells, and has the ability to 
regulate proliferation and differentiation of C2C12 myoblasts. I demonstrate that in 
response to a single bout of ES, AKT is activated (Figure 11), and the same is true with 
longer term-ES (Figure 19 A-C). This may have profound effects within these 
proliferating myoblasts, where it may promote activation GSK-3β and its targets, such 
as myogenin and cyclin D, leading to cell cycle arrest and the onset of the differentiation 
program.  However, long term stimulation was shown to promote cell cycle arrest, while 
limiting the differentiation capacity of the cells (44).  
 Myogenin is a downstream target of AKT and AKT mediated phosphorylation of 
GSK-3β alleviates the repression GSK-3β puts on myogenin.  In response to ES, there 
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is no initial change in myogenin protein levels (Figure 12), although there is a drastic 
reduction in myogenin (0.50 ± 0.11) following 4 days of ES (Figure 19), indicating there 
may be a disconnect between AKT, GSK-3β and myogenin as a result of ES with AKT 
potentially promoting cell survival rather than differentiation. 
 It was previously demonstrated that following 5 days of ES there is an increase in 
AMPK activation via its phosphorylation on T172. In the current study I was unable to 
show AMPK activation after 2 or 4 days (Figure 19D), but there was still a decreased 
cell number in response to ES. Immediately following ES there is an increase in AMPK 
activation (Figure 10), which suggests that AMPK may be an immediate responder to 
ES, and that long term stimulation promotes an increase in its activation that is built up 
over time.  This may lead to increases in p27T198, and alter the p27 subcellular 
localization (Figure 16), thereby causing an increase in association with cyclin E, and 
promoting cell cycle exit. Furthermore, AMPK is an activator of autophagy, and may be 
promoting the short term increase in LC3II/LC3I we see immediately in response to ES. 
 LC3 is an important part of the autophagic pathway. The lipidation of LC3I to 
LC3II indicates it is active and may cause an increase in autophagy. While one bout of 
ES increases LC3I conversion to LC3II, during the longer term (2 and 4 days), ES does 
not (Figure 20). This differs from what was previously found in rhabdomyosarcoma 
cells, in which ES elicited an increase in LC3II following long term stimulation, and was 
thought to act as a cell death pathway, rather than a cell remodelling pathway as 
thought to be the case in these myoblasts (10). 
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